First Turn Management LLC Cuts Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

First Turn Management LLC trimmed its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 4.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,451,037 shares of the company's stock after selling 64,923 shares during the quarter. ORIC Pharmaceuticals accounts for about 2.4% of First Turn Management LLC's holdings, making the stock its 20th largest position. First Turn Management LLC owned about 2.06% of ORIC Pharmaceuticals worth $14,873,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of ORIC. Victory Capital Management Inc. increased its holdings in ORIC Pharmaceuticals by 4.1% during the third quarter. Victory Capital Management Inc. now owns 99,750 shares of the company's stock worth $1,022,000 after buying an additional 3,900 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of ORIC Pharmaceuticals by 71.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,568 shares of the company's stock valued at $139,000 after acquiring an additional 5,646 shares during the period. Hennion & Walsh Asset Management Inc. increased its stake in shares of ORIC Pharmaceuticals by 34.7% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 137,962 shares of the company's stock worth $1,414,000 after purchasing an additional 35,528 shares during the last quarter. Creative Planning bought a new stake in shares of ORIC Pharmaceuticals in the 3rd quarter worth approximately $116,000. Finally, SG Americas Securities LLC purchased a new position in ORIC Pharmaceuticals in the third quarter valued at approximately $714,000. 95.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Oppenheimer decreased their target price on ORIC Pharmaceuticals from $17.00 to $15.00 and set an "outperform" rating for the company in a research report on Tuesday, August 13th. HC Wainwright reissued a "buy" rating and issued a $21.00 price objective on shares of ORIC Pharmaceuticals in a report on Monday, November 4th. Wedbush reaffirmed an "outperform" rating and set a $20.00 price objective on shares of ORIC Pharmaceuticals in a report on Tuesday, November 12th. Wells Fargo & Company assumed coverage on shares of ORIC Pharmaceuticals in a research note on Thursday, October 31st. They issued an "overweight" rating and a $20.00 target price for the company. Finally, Stifel Nicolaus began coverage on shares of ORIC Pharmaceuticals in a research note on Friday, September 6th. They set a "buy" rating and a $20.00 price target on the stock. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $18.29.

ORIC Pharmaceuticals Trading Up 3.9 %

Shares of ORIC stock traded up $0.33 during trading hours on Tuesday, reaching $8.89. The stock had a trading volume of 298,212 shares, compared to its average volume of 518,005. The stock's fifty day simple moving average is $9.66 and its 200 day simple moving average is $9.33. The firm has a market capitalization of $627.34 million, a PE ratio of -4.94 and a beta of 1.13. ORIC Pharmaceuticals, Inc. has a 12 month low of $6.33 and a 12 month high of $16.65.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.01). As a group, equities research analysts anticipate that ORIC Pharmaceuticals, Inc. will post -1.85 EPS for the current fiscal year.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.